Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use JASCAYD safely and effectively. See full prescribing information for JASCAYD. JASCAYD® (nerandomilast tablets), for oral use Initial U.S. Approval: 2025
Medication labelWhy this: Advisory · dailymed-prescription
JASCAYD is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients. JASCAYD is indicated for the treatment of progressive pulmonary fibrosis (PPF) in adult patients.
- generic_name
- nerandomilast
- product_names
- nerandomilast
- ndc
- 0597-2465, 0597-2465-41, 0597-7313, 0597-7313-21
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en